Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial

Radiology. 2020 Sep;296(3):638-640. doi: 10.1148/radiol.2020201370. Epub 2020 Jul 21.

Authors

Ulf Teichgräber¹, Thomas Lehmann¹, René Aschenbach¹, Markus Thieme¹, Thomas Zeller¹, Ulrich Beschorner¹, Dierk Scheinert¹

Affiliation

¹ From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).

PMID: 32692299
DOI: 10.1148/radiol.2020201370

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angioplasty, Balloon* / adverse effects
Angioplasty, Balloon* / mortality
Angioplasty, Balloon* / statistics & numerical data
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Agents, Phytogenic / therapeutic use
Drug-Eluting Stents* / adverse effects
Drug-Eluting Stents* / statistics & numerical data
Femoral Artery / surgery*
Humans
Morbidity
Paclitaxel / administration & dosage
Paclitaxel / adverse effects
Paclitaxel / therapeutic use
Peripheral Arterial Disease* / drug therapy
Peripheral Arterial Disease* / epidemiology
Peripheral Arterial Disease* / mortality
Peripheral Arterial Disease* / surgery
Popliteal Artery / surgery*
Randomized Controlled Trials as Topic

Substances

Antineoplastic Agents, Phytogenic
Paclitaxel